Related Experiment Video
Updated: Nov 30, 2025
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Volker Vallon1,2,3, Subodh Verma4,5
1Division of Nephrology and Hypertension, Department of Medicine, University of California, San Diego, La Jolla, California 92093, USA;
Abstract:
SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients with or without type 2 diabetes and preserved or reduced kidney function from failing. The involved protective mechanisms include blood glucose-dependent and -independent mechanisms: SGLT2 inhibitors prevent both hyper- and hypoglycemia, with expectedly little net effect on HbA1C. Metabolic adaptations to induced urinary glucose loss include reduced fat mass and more ketone bodies as additional fuel. SGLT2 inhibitors lower glomerular capillary hypertension and hyperfiltration, thereby reducing the physical stress on the filtration barrier, albuminuria, and the oxygen demand for tubular reabsorption. This improves cortical oxygenation, which, together with lesser tubular gluco-toxicity, may preserve tubular function and glomerular filtration rate in the long term. SGLT2 inhibitors may mimic systemic hypoxia and stimulate erythropoiesis, which improves organ oxygen delivery. SGLT2 inhibitors are proximal tubule and osmotic diuretics that reduce volume retention and blood pressure and preserve heart function, potentially in part by overcoming the resistance to diuretics and atrial-natriuretic-peptide and inhibiting Na-H exchangers and sympathetic tone.
Insights
Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer significant cardioprotective and nephroprotective benefits. These antihyperglycemic drugs work through glucose-dependent and -independent pathways to preserve kidney and heart function.
Area of Science:
- Pharmacology
- Nephrology
- Cardiology
Background:
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors are antihyperglycemic agents.
- They demonstrate protective effects on the kidneys and heart in patients with or without type 2 diabetes.
Purpose of the Study:
- To elucidate the multifaceted protective mechanisms of SGLT2 inhibitors.
- To detail their impact on glucose regulation, metabolic adaptations, and organ function.
Main Methods:
- Review of SGLT2 inhibitor mechanisms of action.
- Analysis of effects on glucose homeostasis, body composition, and renal hemodynamics.
- Evaluation of impact on oxygenation, erythropoiesis, and cardiovascular parameters.
Main Results:
- SGLT2 inhibitors prevent hyper/hypoglycemia with minimal HbA1C effect.
- They induce metabolic shifts, reduce fat mass, and increase ketone production.
- Lowered glomerular pressure, reduced albuminuria, and improved cortical oxygenation are observed.
- Erythropoiesis stimulation enhances organ oxygen delivery.
- Diuretic effects reduce volume, lower blood pressure, and preserve cardiac function.
Conclusions:
- SGLT2 inhibitors provide comprehensive renal and cardiac protection via diverse mechanisms.
- Their benefits extend beyond glycemic control, impacting metabolism, hemodynamics, and oxygenation.
- These agents represent a significant therapeutic advancement for cardiovascular and kidney protection.
Related Concept Videos
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:24Chronic Kidney Disease II: Clinical Manifestations
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: Diuretics
01:23Dipeptidyl Peptidase 4 Inhibitors
01:22Acute Kidney Injury VI: Nursing Management